Hua's dorzagliatin reduces HbA1c in Phase II for Type II diabetes
Hua Medicine Ltd. (Shanghai, China) reported data from a double-blind, Chinese Phase II trial in 258 Type II diabetics showing that twice-daily 50 and 75 mg doses of oral dorzagliatin (sinogliatin, HMS5552, RO5305552) both significantly reduced mean HbA1c from baseline to week 12 vs. placebo (0.79% and 1.12%, respectively, vs. 0.35%, p=0.0104 and p<0.0001). The once-daily 75 and 100 mg doses of dorzagliatin reduced mean HbA1c from baseline to week 12 by 0.39% and 0.65%, respectively. No treatment-related serious adverse events or cases of severe hypoglycemia were reported. Data were published in The Lancet Diabetes & Endocrinology...
BCIQ Target Profiles